Pneumoconiosis Market Research Report – Global Forecast till 2023

Report / Search Code: MRFR/HC/3218-HCRR  Publish Date: January, 2019

Price

1-user PDF : $ 4450.0
Enterprise PDF : $ 6250.0

Description:

**Pneumoconiosis Market Research Report**, By Type (Asbestosis, Berylliosis, Byssinosis, Coal Workers Pneumoconiosis, Silicosis), Cause (Organic Dusts, Non-Organic Substances), Therapy (Diagnosis, Treatment), End User (Hospital) - Global Forecast till 2023

**Market Scenario:**

Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this disease. According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.

The **global pneumoconiosis market** is expected to grow at a CAGR of 6.8% during forecast period.

**Intended Audience**

- Biotechnological institutes
- Pharmaceutical companies
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories

**Figure 1:** Global Pneumoconiosis market share, by causes
Segmentation

The global pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users.

On the basis of types, the market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others.

On the basis of causes, the market is categorised into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others.

On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others.

On the basis of end users, the market is segmented into hospital, clinics, and others.

Regional Analysis

America dominates the global pneumoconiosis market owing to large patient population. Apart from this, increasing number of patients, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is equals around 36.5 million adults in the United States currently smoke cigarettes. Increasing smoking population increases the possibility of causing the disease. Additionally, increasing awareness among the people regarding different diagnostic procedures and well-developed technology has also contributed to the growth of the market.

Europe is the second largest pneumoconiosis market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and presence of huge opportunity in the market.

On the other hand, the Middle East & Africa has the least share in the global pneumoconiosis market due to presence of poor economy especially in Africa region. Majority of the market of this region is held by Middle East due to well-developed healthcare sector and huge healthcare
Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation

Key players for global pneumoconiosis market

The key players for the global pneumoconiosis market Abbott (US), Eli Lilly (U.S.), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.).
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Pneumoconiosis Market, by Type
6.1 Introduction
6.2 Asbestosis
Market Estimates & Forecast, 2017 – 2023
6.3 Berylliosis
Market Estimates & Forecast, 2017 – 2023
6.4 Byssinosis
Market Estimates & Forecast, 2017 – 2023
6.5 Coal Workers Pneumoconiosis
Market Estimates & Forecast, 2017 – 2023
6.6 Silicosis
Market Estimates & Forecast, 2017 – 2023
6.7 Others
Market Estimates & Forecast, 2017 – 2023

Chapter 7. Global Pneumoconiosis Market, by Causes
7.1 Introduction
7.2 Organic Dusts
Market Estimates & Forecast, 2017 – 2023
7.2.1 Hay
7.2.2 Malt
7.2.3 Mushrooms
7.2.4 Others
7.3 Non-Organic Substances
Market Estimates & Forecast, 2017 – 2023
7.3.1 Sulphur Dioxide
7.3.2 Ammonia
7.3.3 Nitrogen Dioxide
7.3.4 Others
7.4 Others
Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Pneumoconiosis Market, by Therapy
8.1 Introduction
8.2 Diagnosis
Market Estimates & Forecast, 2017 – 2023
8.2.1 X-Ray
8.2.2 CT Scan
8.2.3 Others
8.3 Treatment
Market Estimates & Forecast, 2017 – 2023
8.3.1 Mucolytic Agent
8.3.2 Antibiotic
8.3.3 Others

Chapter 9 Global Pneumoconiosis Market, by End User
9.1 Introduction
9.2 Hospitals
Market Estimates & Forecast, 2017 – 2023
9.3 Clinics
Market Estimates & Forecast, 2017 – 2023
9.4 Others

Chapter 10. Global Pneumoconiosis Market, by Region
10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Novartis AG
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Abbott
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Eli Lilly
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Sunpharma
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Sanofi
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Novo Nordisk
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 AstraZeneca
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Pharmaceutical industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Pneumoconiosis Industry Synopsis, 2017 – 2023
Table 2 Global Pneumoconiosis Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Pneumoconiosis Market by Region, 2017 – 2023, (USD Million)
Table 4 Global Pneumoconiosis Market by Types, 2017 – 2023, (USD Million)
Table 5 Global Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 6 Global Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 7 Global Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 8 North America Pneumoconiosis Market by Types, 2017 – 2023, (USD Million)
Table 9 North America Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 10 North America Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 11 North America Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 12 US Market by Types, 2017 – 2023, (USD Million)
Table 13 US Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 14 US Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 15 US Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 16 Canada Market by Types, 2017 – 2023, (USD Million)
Table 17 Canada Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 18 Canada Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 19 Canada Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 20 South America Market by Types, 2017 – 2023, (USD Million)
Table 21 South America Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 22 South America Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 23 South America Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 24 Europe Market by Types, 2017 – 2023, (USD Million)
Table 25 Europe Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 26 Europe Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 27 Europe Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 28 Western Europe Market by Types, 2017 – 2023, (USD Million)
Table 29 Western Europe Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 30 Western Europe Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 31 Western Europe Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 32 Eastern Europe Market by Types, 2017 – 2023, (USD Million)
Table 33 Eastern Europe Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 34 Eastern Europe Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 35 Eastern Europe Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 36 Asia Pacific Market by Types, 2017 – 2023, (USD Million)
Table 37 Asia Pacific Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 38 Asia Pacific Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 39 Asia Pacific Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)
Table 40 Middle East & Africa Market by Types, 2017 – 2023, (USD Million)
Table 41 Middle East & Africa Pneumoconiosis Market by Causes, 2017 – 2023, (USD Million)
Table 42 Middle East & Africa Pneumoconiosis Market by Therapy, 2017 – 2023, (USD Million)
Table 43 Middle East & Africa Pneumoconiosis Market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Pneumoconiosis Market
Figure 3 Segmentation Market Dynamics for Global Pneumoconiosis Market
Figure 4 Global Pneumoconiosis market Share, by Type 2016
Figure 5 Global Pneumoconiosis market Share, by Causes 2016
Figure 6 Global Pneumoconiosis market Share, by Therapy 2016
Figure 7 Global Pneumoconiosis Market Share, by End Users, 2016
Figure 8 Global Pneumoconiosis Market Share, by Region, 2016
Figure 9 North America Pneumoconiosis Market Share, by Country, 2016
Figure 10 Europe Pneumoconiosis Market Share, by Country, 2016
Figure 11 Asia Pacific Pneumoconiosis Market Share, by Country, 2016
Figure 12 Middle East & Africa Pneumoconiosis Market Share, by Country, 2016
Figure 13 Global Pneumoconiosis Market: Company Share Analysis, 2016 (%)
Figure 14 Novartis AG: Key Financials
Figure 15 Novartis AG: Segmental Revenue
Figure 16 Novartis AG: Geographical Revenue
Figure 17 Abbott: Key Financials
Figure 18 Abbott: Segmental Revenue
Figure 19 Abbott: Geographical Revenue
Figure 20 Eli Lilly: Key Financials
Figure 21 Eli Lilly: Segmental Revenue
Figure 22 Eli Lilly: Geographical Revenue
Figure 23 Sunpharma: Key Financials
Figure 24 Sunpharma: Segmental Revenue
Figure 25 Sunpharma: Geographical Revenue
Figure 26 Sanofi: Key Financials
Figure 27 Sanofi: Segmental Revenue
Figure 28 Sanofi: Geographical Revenue
Figure 29 Novo Nordisk: Key Financials
Figure 30 Novo Nordisk: Segmental Revenue
Figure 31 Novo Nordisk: Geographical Revenue
Figure 32 AstraZeneca: Key Financials
Figure 33 AstraZeneca: Segmental Revenue
Figure 34 AstraZeneca: Geographical Revenue